FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2624151616> ?p ?o ?g. }

• W2624151616 endingPage "53287" @default.
• W2624151616 startingPage "53276" @default.
• W2624151616 abstract "// Yinfeng Guo 1 , Zhixia Song 1 , Min Zhou 1 , Ying Yang 1 , Yu Zhao 1 , Bicheng Liu 1 and Xiaoliang Zhang 1 1 Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu 210009, China Correspondence to: Xiaoliang Zhang, email: tonyxlz@163.com Keywords: macrophage, podocyte, apoptosis, diabetic nephropathy Received: July 04, 2016     Accepted: May 22, 2017     Published: June 07, 2017 ABSTRACT Macrophage infiltration has been linked to the pathogenesis of diabetic nephropathy (DN). However, how infiltrating macrophages affect the progression of DN is unknown. Although infiltrating macrophages produce pro-inflammatory mediators and induce apoptosis in a variety of target cells, there are no studies in podocytes. Therefore, we tested the contribution of macrophages to podocytes apoptosis in DN. in vivo experiments showed that apoptosis in podocytes was increased in streptozocin (STZ)-induced diabetic rats compared with control rats and that this apoptosis was accompanied by increased macrophages infiltration in the kidney. Then, we established a co-culture system to study the interaction between macrophages and podocytes in the absence or presence of high glucose. Macrophages did not trigger podocytes apoptosis when they were co-cultured in the absence of high glucose in a transwell co-culture system. Additionally, although podocyte apoptosis was increased after high glucose stimulation, there was a further enhancement of podocyte apoptosis when podocytes were co-cultured with macrophages in the presence of high glucose compared with podocytes cultured alone in high glucose. Mechanistically, we found that macrophages were activated when they were exposed to high glucose, displaying pro-inflammatory M1 polarization. Furthermore, conditioned media (CM) from such high glucose-activated M1 macrophages (HG-CM) trigged podocytes apoptosis in a reactive oxygen species (ROS)-p38mitogen-activated protein kinases (p38MAPK) dependent manner, which was abolished by either a ROS inhibitor (Tempo) or a p38MAPK inhibitor (SB203580). Finally, we identified tumor necrosis factor (TNF-α) as a key mediator of high glucose-activated macrophages to induce podocytes apoptosis because an anti-TNF-α neutralizing antibody blunted the apoptotic response, excess ROS generation and p38MPAK activation in podocytes induced by HG-CM. Moreover, addition of recombinant TNF-α similarly resulted in podocytes apoptosis. In summary, the TNF-α that was released by high glucose-activated macrophages promoted podocytes apoptosis via ROS-p38MAPK pathway. Blockade of TNF-α secretion from high glucose activated macrophages and ROS-p38MAPK pathway might be effective therapeutic options to limit podocytes apoptosis and delay the progression of diabetic nephropathy." @default.
• W2624151616 created "2017-06-15" @default.
• W2624151616 creator A5019687626 @default.
• W2624151616 creator A5020847968 @default.
• W2624151616 creator A5026927881 @default.
• W2624151616 creator A5043169541 @default.
• W2624151616 creator A5054344543 @default.
• W2624151616 creator A5058396165 @default.
• W2624151616 creator A5063864219 @default.
• W2624151616 date "2017-06-07" @default.
• W2624151616 modified "2023-09-30" @default.
• W2624151616 title "Infiltrating macrophages in diabetic nephropathy promote podocytes apoptosis via TNF-α-ROS-p38MAPK pathway" @default.
• W2624151616 cites W1566290522 @default.
• W2624151616 cites W1984933341 @default.
• W2624151616 cites W1988836590 @default.
• W2624151616 cites W2008445878 @default.
• W2624151616 cites W2013021497 @default.
• W2624151616 cites W2020498525 @default.
• W2624151616 cites W2021485996 @default.
• W2624151616 cites W2043582390 @default.
• W2624151616 cites W2062099357 @default.
• W2624151616 cites W2068165090 @default.
• W2624151616 cites W2078624038 @default.
• W2624151616 cites W2082162080 @default.
• W2624151616 cites W2084141237 @default.
• W2624151616 cites W2085211563 @default.
• W2624151616 cites W2087367592 @default.
• W2624151616 cites W2091754751 @default.
• W2624151616 cites W2095328109 @default.
• W2624151616 cites W2097160036 @default.
• W2624151616 cites W2097887036 @default.
• W2624151616 cites W2101861123 @default.
• W2624151616 cites W2102235083 @default.
• W2624151616 cites W2103813608 @default.
• W2624151616 cites W2106133771 @default.
• W2624151616 cites W2114546557 @default.
• W2624151616 cites W2133304171 @default.
• W2624151616 cites W2158054551 @default.
• W2624151616 cites W2159611825 @default.
• W2624151616 cites W2161361699 @default.
• W2624151616 cites W2171553260 @default.
• W2624151616 cites W2216845378 @default.
• W2624151616 cites W2318779348 @default.
• W2624151616 cites W2338184168 @default.
• W2624151616 cites W2413787065 @default.
• W2624151616 cites W4239470109 @default.
• W2624151616 doi "https://doi.org/10.18632/oncotarget.18394" @default.
• W2624151616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5581109" @default.
• W2624151616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28881810" @default.
• W2624151616 hasPublicationYear "2017" @default.
• W2624151616 type Work @default.
• W2624151616 sameAs 2624151616 @default.
• W2624151616 citedByCount "35" @default.
• W2624151616 countsByYear W26241516162017 @default.
• W2624151616 countsByYear W26241516162018 @default.
• W2624151616 countsByYear W26241516162019 @default.
• W2624151616 countsByYear W26241516162020 @default.
• W2624151616 countsByYear W26241516162021 @default.
• W2624151616 countsByYear W26241516162022 @default.
• W2624151616 countsByYear W26241516162023 @default.
• W2624151616 crossrefType "journal-article" @default.
• W2624151616 hasAuthorship W2624151616A5019687626 @default.
• W2624151616 hasAuthorship W2624151616A5020847968 @default.
• W2624151616 hasAuthorship W2624151616A5026927881 @default.
• W2624151616 hasAuthorship W2624151616A5043169541 @default.
• W2624151616 hasAuthorship W2624151616A5054344543 @default.
• W2624151616 hasAuthorship W2624151616A5058396165 @default.
• W2624151616 hasAuthorship W2624151616A5063864219 @default.
• W2624151616 hasBestOaLocation W26241516161 @default.
• W2624151616 hasConcept C121332964 @default.
• W2624151616 hasConcept C126322002 @default.
• W2624151616 hasConcept C134018914 @default.
• W2624151616 hasConcept C150903083 @default.
• W2624151616 hasConcept C153400128 @default.
• W2624151616 hasConcept C190283241 @default.
• W2624151616 hasConcept C202751555 @default.
• W2624151616 hasConcept C207001950 @default.
• W2624151616 hasConcept C2777146197 @default.
• W2624151616 hasConcept C2779244956 @default.
• W2624151616 hasConcept C2779561371 @default.
• W2624151616 hasConcept C2779922275 @default.
• W2624151616 hasConcept C2780091579 @default.
• W2624151616 hasConcept C2781184683 @default.
• W2624151616 hasConcept C502942594 @default.
• W2624151616 hasConcept C55493867 @default.
• W2624151616 hasConcept C555293320 @default.
• W2624151616 hasConcept C71924100 @default.
• W2624151616 hasConcept C86803240 @default.
• W2624151616 hasConcept C95444343 @default.
• W2624151616 hasConcept C97355855 @default.
• W2624151616 hasConceptScore W2624151616C121332964 @default.
• W2624151616 hasConceptScore W2624151616C126322002 @default.
• W2624151616 hasConceptScore W2624151616C134018914 @default.
• W2624151616 hasConceptScore W2624151616C150903083 @default.
• W2624151616 hasConceptScore W2624151616C153400128 @default.
• W2624151616 hasConceptScore W2624151616C190283241 @default.
• W2624151616 hasConceptScore W2624151616C202751555 @default.
• W2624151616 hasConceptScore W2624151616C207001950 @default.

• next